The Crucial Role of Phase I Clinical Trials in Advancing Medicine; by David Walling, PhD The journey from a promising scientific discovery to a safe and effective medication available to the public is a complex and rigorous process. At the heart of this...
News at CenExel
Advancements in Vaccines: Bridging the Past and Future
Advancements in Vaccines: Bridging the Past and Future - by Nelia Sanchez-Crespo, MD The history of vaccines is a testament to the incredible progress we've made in protecting humanity against infectious diseases. From the invention of the smallpox...
A link between seizure and stuttering disorders? A case report
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.
Join CenExel at CNS Summit 2021
CenExel Clinical Research Network is excited to announce our presence at the upcoming CNS Summit 2021 in Boston, Massachusetts on November 7-11, 2021. The mission of the CNS Summit is to have a positive impact on the success of clinical development programs as an...
CenExel Clinical Research Acquires CITrials
Salt Lake City, Mar. 9, 2021 /PRNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of CITrials, a southern California-based clinical research firm with three sites serving Los Angeles, Orange, and Riverside/San Bernardino counties....